Previous 10 | Next 10 |
home / stock / nrx:cc / nrx:cc news
The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meeting A pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into t...
Results indicate that the proprietary production process boosts exosome productivity, improving cost-efficiency Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologica...
Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Comp...
Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality Assurance Company to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM EST Calgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExo...
Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality Assurance Company to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM EST Calgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExo...
Results show a significant increase in effectiveness of NurExone's therapeutic compounds in inhibition of PTEN expression Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing ...
Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome ther...
Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased t...
Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, anno...
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the " Company " or " NurExone "), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, released excerpts fr...
News, Short Squeeze, Breakout and More Instantly...
NurExone Biologic Inc. Company Name:
NRX:CC Stock Symbol:
TSXVC Market:
NurExone Biologic Inc. Website:
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale cont...
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at ad...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the...